An observational study in Sickle Cell Disease, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Anemia, Sickle Cell with a site in Italy — 9 open to participants now, 16 under way, 9 of them phase 3. Anemia, Sickle Cell · Italy.
Among the 43 studies in Anemia, Sickle Cell with a site in Italy, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 9 that started in 2022, is one of 10 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 41st registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →9 of the 43 studies in Anemia, Sickle Cell with a site in Italy are open now. Recruiting first, the newest first:
CSL Behring · Sites in Italy, United States, Belgium and 4 more countries
Ages 18+
Sanofi · Sites in Italy, United States, Belgium and 11 more countries
Ages 10–65
Novo Nordisk A/S · Sites in Italy, United States, Australia and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in Italy, United States, Canada and 14 more countries
Ages 2+
Bristol-Myers Squibb · Sites in Italy, United States, Canada and 2 more countries
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 17 · Phase 4 1
First in 2004; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 160 across the 33 interventional studies, 1,250 across the 10 observational. Of the 27 that completed or were terminated, 17 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 43 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.
Hospital Universitari Vall d'Hebron Research Institute has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
7 of the studies in Anemia, Sickle Cell with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT06975865Phase 3SanofiThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | 2027-07-23 |
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT06794281Hospital Universitari Vall d'Hebron Research InstituteSynthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case | 2026-11-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 43 studies in Anemia, Sickle Cell with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Haematological diseases (HDs) are a large group of disorders resulting from quantitative or qualitative abnormalities of blood cells, lymphoid organs and coagulation factors. Despite most of them (\~74%) are rare, the overall number of HD affected patients worldwide is important, placing a considerable economic burden on healthcare systems and societies. Despite the existence of several collaborative research groups at national and EU level, current clinical approaches are often ineffective, particularly for rarest conditions, due to the relatively low number of patients per disease and the high number of unconnected clinical entities.
SYNTHEMA aims to establish a cross-border data hub where to develop and validate innovative AI-based techniques for clinical data anonymisation and synthetic data generation (SDG), to tackle the scarcity and fragmentation of data and widen the basis for GDPR-compliant research in rare hematological disorders (RHD). The project will focus on one representative RHD use case: sickle-cell disease (SCD).
SYNTHEMA will develop a federated learning (FL) infrastructure, equipped with secure multiparty computation (SMPC) and differential privacy (DF) protocols, connecting clinical centres bringing standardised, interoperable multimodal datasets and computing centres from academia and SME. This framework will be utilised to train the developed algorithms and perform SMPC-based global model aggregation in a privacy-preserving fashion. The resulting data will be validated for their clinical value, statistical utility and residual privacy risks. The project will develop legal and ethical frameworks to guarantee privacy by-design in the collection and processing of health-related personal data and attain an ethics-wise algorithm co-creation. Project outcomes, including pipelines, standards and data, will be made openly available to stakeholders in the healthcare, academia and industry field, and contribute to existing rare disease registries
SYNTHEMA will retrospectively collect existing RHD clinical, omics and imaging datasets from all the health data centres of its consortium (VHIR, UMCU, GLSMED LH, UNIPD) for the target SCD clinical use cases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result. O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care. O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation. O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs. O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices.
Also known as: Synthetic Data Generation
Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result
For Sickle Cell Disease, validation scenarios will test the reliability of synthetic data in regards to genomic variants/disease phenotypes association and MRI feature-based prediction of brain vascular events (SCD).
Time frame: November 2026
Plan to share: No
Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute →